Skip to main content
. 2019 Oct 11;10:1184. doi: 10.3389/fphar.2019.01184

Figure 1.

Figure 1

Neoantigen-primed personalized DC vaccines for refractory NSCLC. We utilized whole-exome sequencing of tumor tissues, computational epitope prediction, and immunological approaches to screen for neoantigens from individual patients, and then infused autologous DCs pulsed with neoantigen-derived peptides into each patient (ClinicalTrials.gov Identifier: NCT02956551).